

Prevalence of COVID-19 among patients with rheumatic diseases: the need to await results from large collaborative studies. Response to: 'COVID-19 pneumonia in a large cohort of patients treated with biological and targeted synthetic antirheumatic drugs' by Conticini *et al*

We thank Dr Conticini *et al*¹ for their comment on our previously published paper describing the course of COVID-19 in a cohort of patients treated with biologic and targeted synthetic disease-modifying anti-rheumatic drugs (b/tsDMARDs).² The authors commented on the low prevalence of subjects treated with bDMARDs in our cohort of patients affected by COVID-19; however, our paper actually described the course of severe acute respiratory coronavirus-2 (SARS-CoV-2) infection in the cohort of patients attending our biologic clinic rather than the opposite. Nonetheless, assessing the prevalence of COVID-19 in patients treated with b/tsDMARDs was out of the scope of our study.² The main message that can be drawn by observational studies on our and other smaller cohorts of patients with rheumatic diseases such as the one reported by Conticini *et al*¹ is that, in our limited series of patients, SARS-CoV-2 infection did not seem to have a worse course or outcome compared with the general population. We have previously highlighted how a high degree of caution should be applied when interpreting these results and when assessing an immunocompromised patient with COVID-19. Large, multicentre, national and international cohorts have been launched to actively recruit patients such as the Italian Society of Rheumatology-sponsored registry (COVID-19-RMD) or the European EULAR-COVID-19 Database.³ The results from these large cohorts are awaited to properly assess the incidence and prevalence of COVID-19 among rheumatological patients and the clinical implications on this susceptible population. The evaluation of the epidemiology of COVID-19 among patients with rheumatic diseases will need to take into account the potential impact that the use of immunomodulatory drugs may have both on the course of the infection and on the careful preventive behavioural changes that our patients affected by chronic conditions might have adopted to protect themselves during the pandemic. The geographical differences of COVID-19 distribution among different Italian regions and in Europe should also be considered when evaluating the impact of the infection on rheumatological diseases populations.

Sara Monti , Carlomaurizio Montecucco

Rheumatology, Fondazione IRCCS Policlinico San Matteo, Pavia, Lombardia, Italy

Correspondence to Dr Sara Monti, Rheumatology, Fondazione IRCCS Policlinico San Matteo, Pavia 27100, Italy; sara.saramonti@gmail.com

Handling editor Josef S Smolen

Contributors SM and CM contributed equally to the manuscript.

Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

Competing interests None declared.

Patient and public involvement Patients and/or the public were not involved in the design, or conduct, or reporting, or dissemination plans of this research.

Patient consent for publication Not required.

Provenance and peer review Commissioned; internally peer reviewed.

This article is made freely available for use in accordance with BMJ's website terms and conditions for the duration of the covid-19 pandemic or until otherwise determined by BMJ. You may use, download and print the article for any lawful, non-commercial purpose (including text and data mining) provided that all copyright notices and trade marks are retained.

© Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and permissions. Published by BMJ.



To cite Monti S, Montecucco C. *Ann Rheum Dis* 2021;**80**:e15.

Received 27 April 2020

Revised 1 May 2020

Accepted 2 May 2020

Published Online First 15 May 2020



► <http://dx.doi.org/10.1136/annrheumdis-2020-217681>

Ann Rheum Dis 2021;**80**:e15. doi:10.1136/annrheumdis-2020-217738

ORCID iD

Sara Monti <http://orcid.org/0000-0002-1800-6772>

REFERENCES

- Conticini E, Bargagli E, Bardelli M. COVID-19 pneumonia in a large cohort of patients treated with biologic and targeted synthetic anti-rheumatic drugs. *Ann Rheum Dis* 2021;**80**:e14.
- Monti S, Balduzzi S, Delvino P, *et al*. Clinical course of COVID-19 in a series of patients with chronic arthritis treated with immunosuppressive targeted therapies. *Ann Rheum Dis* 2020;**79**:667–8.
- McInnes IB. COVID-19 and rheumatology: first steps towards a different future? *Ann Rheum Dis* 2020;**79**:551–2.